In VivoThe concept of RNA as a medicine is not new. The act of using ribonucleic acid molecules to treat or prevent diseases by affecting biological pathways has been pursued for almost 50 years. Antisense o
ScripAstraZeneca PLC will pay $75m to team up with Scorpion Therapeutics, Inc. and discover, develop and commercialize precision medicines against cancer proteins. Under the terms of the agreement, Scor
ScripIt was a successful quarter for the UK biotech sector, driven by a string of sizeable venture capital deals, initial public offerings and follow-on financings and the money has continued to roll in th
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Genentech Seeks Novel Small Molecule Ca